# A Pilot Trial of Clazakizumab in Late ABMR

> **NCT03444103** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 20 (actual)

## Conditions studied

- Antibody-mediated Rejection

## Interventions

- **DRUG:** Clazakizumab / Clazakizumab
- **DRUG:** Placebo / Clazakizumab

## Key facts

- **NCT ID:** NCT03444103
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-16
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-09-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03444103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03444103, "A Pilot Trial of Clazakizumab in Late ABMR". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03444103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*